Hepatobiliary phase liver MR imaging findings after Oxaliplatin-based chemotherapy in cancer patients

  • Emre Ünal
  • Ali Devrim Karaosmanoğlu
  • Mustafa Nasuh Ozmen
  • Deniz Akata
  • Musturay Karcaaltincaba
Pictorial essay



To describe Gd-EOB-DTPA-enhanced liver MR imaging findings in colon and rectal cancer patients who received Oxaliplatin.


Spectrum of hepatobiliary phase imaging findings include diffuse heterogeneous dysfunction, macronodular and micronodular FNH-like lesions, and coexistence of periportal increased liver function with FNH-like lesions. Differentiation of these benign lesions from metastasis is crucial to avoid biopsy in patients with colorectal cancers and may allow better understanding of sinusoidal obstruction syndrome pathophysiology and regenerative response of liver.


Sinusoidal obstruction syndrome Oxaliplatin FNH-like lesion Colorectal cancer Gd-EOB-DTPA Hepatobiliary phase Liver MRI 


Compliance with ethical standards


The authors received no financial support for the research, authorship, and/or publication of this paper.

Conflict of interest

Authors declare that they have no conflict of interest.

Ethical approval

This paper does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Aloia T, Sebagh M, Plasse M, et al. (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24:4983–4990CrossRefPubMedGoogle Scholar
  2. 2.
    Morine Y, Shimada M, Utsunomiya T (2014) Evaluation and management of hepatic injury induced by oxaliplatin-based chemotherapy in patients with hepatic resection for colorectal liver metastasis. Hepatol Res 44:59–69CrossRefPubMedGoogle Scholar
  3. 3.
    Rubbia-Brandt L, Lauwers GY, Wang H, et al. (2010) Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56:430–439CrossRefPubMedGoogle Scholar
  4. 4.
    Han NY, Park BJ, Sung DJ, et al. (2014) Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxetic acid-enhanced and diffusion-weighted MR imaging with clinical–pathologic correlation. Radiology 271:416–425CrossRefPubMedGoogle Scholar
  5. 5.
    Shin NY, Kim MJ, Lim JS, et al. (2012) Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 22:864–871CrossRefPubMedGoogle Scholar
  6. 6.
    Narita M, Oussoultzoglou E, Chenard MP, et al. (2011) Sinusoidal obstruction syndrome compromises liver regeneration in patients undergoing two-stage hepatectomy with portal vein embolization. Surg Today 41:7–17CrossRefPubMedGoogle Scholar
  7. 7.
    Mehta NN, Ravikumar R, Coldham CA, et al. (2008) Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol 34:782–786CrossRefPubMedGoogle Scholar
  8. 8.
    Nakano H, Oussoultzoglou E, Rosso E, et al. (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247:118–124CrossRefPubMedGoogle Scholar
  9. 9.
    Arakawa Y, Shimada M, Utsunomya T, et al. (2013) Oxaliplatin-related sinusoidal obstruction syndrome mimicking metastatic liver tumors. Hepatol Res 43:685–689CrossRefPubMedGoogle Scholar
  10. 10.
    Choi JH, Won YW, Kim HS, et al. (2016) Oxaliplatin-induced sinusoidal obstruction syndrome mimicking metastatic colon cancer in the liver. Oncol Lett 11:2861–2864CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Overman MJ, Maru DM, Charnsangavej C, et al. (2010) Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28:2549–2555CrossRefPubMedGoogle Scholar
  12. 12.
    Ward J, Guthrie JA, Sheridan MB, et al. (2008) Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. J Clin Oncol 26:4304–4310CrossRefPubMedGoogle Scholar
  13. 13.
    Han NY, Park BJ, Yang KS, et al. (2017) Hepatic parenchymal heterogeneity as a marker for oxaliplatin-induced sinusoidal obstruction syndrome: correlation with treatment response of colorectal cancer liver metastases. AJR Am J Roentgenol 209:1–7CrossRefGoogle Scholar
  14. 14.
    Donadon M, Di Tommaso L, Roncalli M, Torzilli G (2013) Multiple focal nodular hyperplasias induced by oxaliplatin-based chemotherapy. World J Hepatol 5:340–344CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV (2009) Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 29:1725–1748CrossRefPubMedGoogle Scholar
  16. 16.
    Yoneda N, Matsui O, Kitao A, et al. (2012) Hepatocyte transporter expression in FNH and FNH-like nodule: correlation with signal intensity on gadoxetic acid enhanced magnetic resonance images. Jpn J Radiol 30:499–508CrossRefPubMedGoogle Scholar
  17. 17.
    Yoneda N, Matsui O, Kitao A, et al. (2016) Benign hepatocellular nodules: hepatobiliary phase of gadoxetic acid-enhanced MR imaging based on molecular background. Radiographics 36:2010–2027CrossRefPubMedGoogle Scholar
  18. 18.
    Dioguardi Burgio M, Ronot M, Salvaggio G, Vilgrain V, Brancatelli G (2016) Imaging of hepatic focal nodular hyperplasia: pictorial review and diagnostic strategy. Semin Ultrasound CT MR 37:511–524CrossRefPubMedGoogle Scholar
  19. 19.
    Benz-Bohm G, Hero B, Gossmann A, et al. (2010) Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma: how much diagnostic imaging is necessary? Eur J Radiol 74:e1–e5CrossRefPubMedGoogle Scholar
  20. 20.
    Bouyn CI, Leclere J, Raimondo G, et al. (2003) Hepatic focal nodular hyperplasia in children previously treated for a solid tumor. Incidence, risk factors, and outcome. Cancer 97:3107–3113CrossRefPubMedGoogle Scholar
  21. 21.
    Marin D, Galluzzo A, Plessier A, et al. (2011) Focal nodular hyperplasia-like lesions in patients with cavernous transformation of the portal vein: prevalence, MR findings and natural history. Eur Radiol 21:2074–2082CrossRefPubMedGoogle Scholar
  22. 22.
    Smith EA, Salisbury S, Martin R, Towbin AJ (2012) Incidence and etiology of new liver lesions in pediatric patients previously treated for malignancy. AJR Am J Roentgenol 199:186–191CrossRefPubMedGoogle Scholar
  23. 23.
    Yoo SY, Kim JH, Eo H, et al. (2013) Dynamic MRI findings and clinical features of benign hypervascular hepatic nodules in childhood-cancer survivors. AJR Am J Roentgenol 201:178–184CrossRefPubMedGoogle Scholar
  24. 24.
    Cha DI, Yoo SY, Kim JH, Jeon TY, Eo H (2014) Clinical and imaging features of focal nodular hyperplasia in children. AJR Am J Roentgenol 202:960–965CrossRefPubMedGoogle Scholar
  25. 25.
    Joyner BL Jr, Levin TL, Goyal RK, Newman B (2005) Focal nodular hyperplasia of the liver: a sequela of tumor therapy. Pediatr Radiol 35:1234–1239CrossRefPubMedGoogle Scholar
  26. 26.
    Kitao A, Zen Y, Matsui O, et al. (2010) Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging-correlation with molecular transporters and histopathologic features. Radiology 256:817–826CrossRefPubMedGoogle Scholar
  27. 27.
    Wanless IR (1990) Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 11:787–797CrossRefPubMedGoogle Scholar
  28. 28.
    Fujiwara H, Sekine S, Onaya H, et al. (2011) Ring-like enhancement of focal nodular hyperplasia with hepatobiliary-phase Gd-EOB-DTPA-enhanced magnetic resonance imaging: radiological–pathological correlation. Jpn J Radiol 29:739–743CrossRefPubMedGoogle Scholar
  29. 29.
    Vander Borght S, Libbrecht L, Blokzijl H, et al. (2005) Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver. J Pathol 207:471–482CrossRefPubMedGoogle Scholar
  30. 30.
    Pawlik TM, Olino K, Gleisner AL, et al. (2007) Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11:860–868CrossRefPubMedGoogle Scholar
  31. 31.
    Vauthey JN, Pawlik TM, Ribero D, et al. (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065–2072CrossRefPubMedGoogle Scholar
  32. 32.
    Hamer OW, Aguirre DA, Casola G, et al. (2006) Fatty liver: imaging patterns and pitfalls. Radiographics 26:1637–1653CrossRefPubMedGoogle Scholar
  33. 33.
    Jang JK, Jang HJ, Kim JS, Kim TK (2017) Focal fat deposition in the liver: diagnostic challenges on imaging. Abdom Radiol (NY) 42:1667–1678CrossRefGoogle Scholar
  34. 34.
    Unal E, Karaosmanoglu AD, Akata D, Ozmen MN, Karcaaltincaba M (2016) Invisible fat on CT: making it visible by MRI. Diagn Interv Radiol 22:133–140CrossRefPubMedGoogle Scholar
  35. 35.
    Karaosmanoglu AD, Onur MR, Ozmen MN, Akata D, Karcaaltincaba M (2016) Magnetic resonance imaging of liver metastasis. Semin Ultrasound CT MR 37:533–548CrossRefPubMedGoogle Scholar
  36. 36.
    Unal E, Akata D, Karcaaltincaba M (2016) Liver function assessment by magnetic resonance imaging. Semin Ultrasound CT MR 37:549–560CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Emre Ünal
    • 1
  • Ali Devrim Karaosmanoğlu
    • 1
  • Mustafa Nasuh Ozmen
    • 1
  • Deniz Akata
    • 1
  • Musturay Karcaaltincaba
    • 1
  1. 1.Liver Imaging Team, Department of RadiologyHacettepe University School of MedicineAnkaraTurkey

Personalised recommendations